Literature DB >> 2575492

Comparative pharmacokinetics of 3'-azido-3'-deoxythymidine (AZT) and 3'-azido-2',3'-dideoxyuridine (AZddU) in mice.

K J Doshi1, J M Gallo, F D Boudinot, R F Schinazi, C K Chu.   

Abstract

The pharmacokinetics of 3'-azido-3'-deoxythymidine (AZT) and 3'-azido-2',3'-dideoxyuridine (AZddU, CS-87), active anti-HIV compounds, were characterized in uninfected mice. Sensitive and specific HPLC techniques were used to quantitate AZT and AZddU concentrations in serum and brain homogenates following iv doses of 50 mg/kg and 250 mg/kg. The pharmacokinetic parameters of t1/2, CIt, and Vss were similar for both compounds at each dose; however, CIt and Vss decreased at the higher dose, indicating a dose dependency. At the 50 mg/kg doses, the CIt of AZddU and AZT was 1.27 liters/hr/kg and 1.38 liters/hr/kg, respectively, which is analogous to the clearance value of AZT observed in humans. Brain/serum concentration ratios for AZddU tended to be greater than those obtained for AZT and were significantly different at the 50 mg/kg dose, being 0.234 +/- 0.282 for AZddU and 0.064 +/- 0.025 for AZT.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2575492

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  7 in total

1.  Hybrid pharmacokinetic models to describe anti-HIV nucleoside brain disposition following parent and prodrug administration in mice.

Authors:  J M Gallo; J T Etse; K J Doshi; F D Boudinot; C K Chu
Journal:  Pharm Res       Date:  1991-02       Impact factor: 4.200

2.  Pharmacokinetics of the anti-human immunodeficiency virus nucleoside analog stavudine in cynomolgus monkeys.

Authors:  S Kaul; K A Dandekar
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

3.  Investigation of the role of breast cancer resistance protein (Bcrp/Abcg2) on pharmacokinetics and central nervous system penetration of abacavir and zidovudine in the mouse.

Authors:  Nagdeep Giri; Naveed Shaik; Guoyu Pan; Tetsuya Terasaki; Chisato Mukai; Shinji Kitagaki; Naoki Miyakoshi; William F Elmquist
Journal:  Drug Metab Dispos       Date:  2008-04-28       Impact factor: 3.922

Review 4.  Antiretroviral bioanalysis methods of tissues and body biofluids.

Authors:  Robin DiFrancesco; Getrude Maduke; Rutva Patel; Charlene R Taylor; Gene D Morse
Journal:  Bioanalysis       Date:  2013-02       Impact factor: 2.681

5.  Pharmacokinetics, oral bioavailability, and metabolic disposition in rats of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine, a nucleoside analog active against human immunodeficiency virus and hepatitis B virus.

Authors:  L W Frick; L St John; L C Taylor; G R Painter; P A Furman; D C Liotta; E S Furfine; D J Nelson
Journal:  Antimicrob Agents Chemother       Date:  1993-11       Impact factor: 5.191

6.  Pharmacokinetics of the anticancer agent 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine in rats.

Authors:  M Qian; X Wang; K Shanmuganathan; C K Chu; J M Gallo
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

7.  Bile duct ligation enhances AZT CNS toxicity partly by impairing the expression and function of BCRP in rat brain.

Authors:  Yuan-Yuan Qin; Ping Xu; Tong Wu; Chao-Qun Qian; Yi-Lin Fan; Dong-Hao Gen; Liang Zhu; Wei-Min Kong; Han-Yu Yang; Feng Xu; Yi-Ting Yang; Li Liu; Xiao-Dong Liu
Journal:  Acta Pharmacol Sin       Date:  2019-05-29       Impact factor: 6.150

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.